
BOB CHAMPION CANCER TRUST

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2019

BOB CHAMPION CANCER TRUST

CONTENTS

	Page
Reference and administrative details of the charity, its trustees and advisers	1 - 2
Trustees' report	3 - 7
Independent examiner's report	8 - 9
Statement of financial activities	10
Balance sheet	11
Notes to the financial statements	12 - 23

BOB CHAMPION CANCER TRUST

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 30 JUNE 2019**

FOUNDER

Professor Sir Michael Peckham MD FRCP FRCR

PRESIDENT

Bob Champion, M.B.E.

MEDICAL ADVISOR

Professor David Dearnaley

VICE PRESIDENTS

Clare Balding, O.B.E.

Willie Carson, O.B.E.

Kristina Cook

David Gower, M.B.E.

Jonjo O'Neill

Greg Rusedski, Esq

Peter Shilton, O.B.E.

Nick Skelton, O.B.E.

TRUSTEES

Michael I Cattermole, Esq. (Chairman)

Alex Embiricos

Timothy Fox, Esq.

Andrew Franklin, Esq.

Catherine McAleavey (appointed 2 July 2019)

Catherine Nash

Luke Ponsonby, Esq.

Bridget Rosser

Carolyn Jane Zetter Wells

TRUST OFFICERS

Mrs Lucienne Wilkinson

Miss Kate Hall

BOB CHAMPION CANCER TRUST

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 30 JUNE 2019**

Advisers (continued)

Charity registered number

1024664

Principal office

Unit D Molasses House
Clove Hitch Quay
Plantation Wharf
London
SW11 3TN

Secretary

Mrs. Lucienne Wilkinson

Chief executive officer

Mrs. Lucienne Wilkinson

Accountants

Ecovis Wingrave Yeats UK Limited
Waverley House
7-12 Noel Street
London
W1F 8GQ

BOB CHAMPION CANCER TRUST

TRUSTEES' REPORT FOR THE YEAR ENDED 30 JUNE 2019

The Trustees present their report and the accounts for the year ended 30th June 2019.

Administrative Details

A Declaration of Trust formed the Charity on 29 June 1993 registered number 1024664. The purpose of the establishment of this charitable trust was to take over and enlarge the work of the Bob Champion Cancer Trust that was set up by a Declaration of Trust dated 20 January 1983.

The number of Trustees shall not be less than three or more than ten. The power of appointing new Trustees is vested in the Trustees and may be exercised by a resolution in writing signed by all of the current Trustees and the new Trustee. The Trustees meet four times per calendar year.

Please see page 1 for Trustee details, legal and other administrative detail.

Structure, Governance and Management

The Trust was set up to support research into the causation, nature and treatment of patients with testicular cancer and other forms of malignant disease including those of the prostate.

The Trustees acknowledge their responsibility for ensuring that the major risks to which the Charity is exposed are identified and systems designed to mitigate those risks. During the year the Trustees completed a formal risk management process to assess business risks and risk management strategies.

The Trust has an independent Medical Advisor, Professor David Dearnaley, to advise the board in their selection of grant awards and allow the Charity to operate in open competition with peer review.

Objectives and Activities

The Bob Champion Cancer Trust currently supports cancer research within the Institute of Cancer Research, The Royal Marsden Hospital in Sutton, Surrey and the Bob Champion Research and Education Building, situated in the Norwich Research Park at the University of East Anglia. The focus of this support is on urological cancers, especially those of the prostate and testis.

The Trust opened in collaboration with the Institute of Cancer Research The Bob Champion Research Centre in 2000, which forms part of the first male dedicated cancer research centre in Europe. This centre is based at The Institute of Cancer Research in Sutton, Surrey.

In February 2015 the Trust with The University of East Anglia (UEA) opened The Bob Champion Research and Education Building at The Norwich Research Park, this facility is operated by the UEA in partnership with the Norfolk & Norwich Hospital. This centre provides state-of-the-art laboratories for researchers to explore new treatments not only for prostate cancer research but for diseases from antibiotic resistance to musculo-skeletal and gastrointestinal diseases.

The Trust is self-supporting and relies totally upon donations from the public that may be in the form of a legacy or cash donation plus gift aid. Income is raised from active social media campaigns and appeals plus a full fundraising calendar. Events range from dinners, golf days, sponsored rides and walks, horse shows, to coffee mornings, cake and book sales. Annual events include a tennis tournament in Battersea Park, the event's 20th anniversary will be held in 2020, the Jump Legends Charity Race held at Chepstow Racecourse and a London quiz night. A very successful carol concert, Carols & Champagne, is held every other year at Chelsea Old Church in London.

BOB CHAMPION CANCER TRUST

TRUSTEES' REPORT (continued) FOR THE YEAR ENDED 30 JUNE 2019

The Trust also enjoys support from individuals and groups taking on personal challenges including mass events such as The London Marathon and Ride London. Access to fundraising platforms such as [www.justgiving](http://www.justgiving.com) and [www.virginmoneygiving](http://www.virginmoneygiving.com) have really helped to encourage people to raise funds for charity whilst achieving a personal goal.

The Trust continues to be involved with the very popular Shetland Pony Grand National. The heats, which Bob Champion attends, are held during the year at County Shows and major horse shows like Badminton and Burghley, with the winning young riders being selected to compete at Olympia. Races are held daily during the six days of the International Horse Show at Olympia every December. Bob Champion is heavily involved with the event, encouraging and advising the participants throughout the year and attends every day at Olympia. The children who are selected to ride at Olympia and the Liverpool Horse Show are asked to gain sponsorship to compete, these funds support the Trust, the target is £1,000 per rider.

Since 1988 the Trust has produced its own, especially commissioned, double sided Christmas card. The card not only raises funds but spreads awareness of the cause and the work of the Trust. The artist/s is selected each year and kindly donates their time and skills in support of the Trust.

Bob Champion still attends many of the events himself and continues to play an integral part in raising funds, and awareness, not only of the Charity's aims, but also of the disease itself. A high proportion of the events are organised from the office, but if not, then help is always offered and support given as in our league of friends etc. Some events operate with the help of a specific event committee, these committees are made up from a wide league of friends, volunteers and keen supporters. The Trust is always open to new fundraising ideas and how to help sufferers, their family and friends.

Achievements and performance

Each year in the UK of the 47,000 men, who will be diagnosed with prostate cancer, more than 11,000 can expect to die from their disease. Significant improvements, therefore, also need to be made in the treatment of this disease.

For many cancers the fundamental mechanism of cancer development has been unravelled. Such studies reveal that the disease develops because of alterations or mutations within 'cancer genes'. Although cancer genes responsible for the development of, for example, colon cancer and breast cancer are well characterised, relatively little is known about the fundamental development of prostate cancer. This is bad news for sufferers of prostate cancer because cancer genes, once found, can be used to aid treatment and act as targets for new drugs.

A particular problem is the highly variable natural history of prostate cancer causes significant problems in its clinical management. Over-treatment of prostate cancers is a particular concern leading to impotence in a high proportion of cases. This is especially true for PSA screen-detected cancers that are mostly biologically irrelevant and in the absence of treatment would never become life threatening. Conversely, more conservative approaches to disease detection and management may leave potentially aggressive cancers untreated.

The Bob Champion Cancer Trust funded a breakthrough leading to the identification of a new class of prostate cancer called DESNT cancer. Patients with DESNT cancer have a very poor outcome. The use of this new prostate cancer classification will allow patients treated with radical therapies such as surgery and radiotherapy to be targeted to men with aggressive cancers, so that the remainder with biologically unimportant disease can be spared the side effects of treatment. Following this breakthrough the Trust funded a project aimed at identifying improved clinical markers (biomarkers) that will allow radical therapies such as surgery and radiotherapy to be targeted to men with significant cancers, so that the remainder, with biologically unimportant disease, are spared the side-effects of treatment. This project focuses on the use of urine exosomes (small fat covered vesicles given off by cancer cells) to monitor the cancer gene expression. Progress has been made in the development of this non-invasive Prostate Urine Risk (PUR) Test. The test will help clinical management as suggested as it determines if a person is a low, intermediate, or high risk of developing aggressive prostate cancer. This work forms part of a Global Urine Biomarker initiative, run by Professor Colin Cooper and involving Centres in Canada, USA, UK and Europe, aimed at identifying biomarkers of aggressive prostate cancer.

BOB CHAMPION CANCER TRUST

**TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 30 JUNE 2019**

Professor Cooper, Chair of Cancer Genetics at the University of East Anglia, Associate Dean of Research in the Faculty of Medical Health runs the ICGC Prostate Cancer Project. These themes form the basis of projects currently funded by the Trust at UEA.

At the Institute of Cancer Research (ICR) the Trust continues to be involved in a prostate cancer sequencing project headed by Professor Ros Eeles. This project aims to identify genetic changes in early onset prostate cancer, to determine if these changes are associated with more aggressive disease, and to identify targets for treatment and screening. Professor Ros Eeles is a clinician as well as a scientist, running both a laboratory at the ICR and a Cancer Genetics and Uro-Oncology Clinic at the Royal Marsden Hospital. She has been instrumental in ensuring new discoveries in cancer genetics immediately benefit patients, particularly in prostate cancer.

Dr Mahedi Hassen, a computational biologist with 10 years research experience, has been awarded the Bob Champion post-doctoral fellowship. This position is within Professor Attard's Team, which although based at UCL, is a collaborative between the ICR with the computational team in the Centre for Evolution and Cancer (CEC) and at the University College London Cancer Institute. Dr Hassen will implement the BCCT pipeline in 400 STAMPEDE samples and using a number of clustering and unsupervised hierarchical techniques, he will stratify patients into groups that will then be evaluated (in collaboration with the MRC Clinical Trials Unit) for a clinical utility using linked clinical data from men participating in the trial.

Publications:-

Gihawi A, Rallapalli G, Hurst R, Cooper CS, Leggett RM, Brewer DS. SEPATH: benchmarking the search for pathogens in human tissue whole genome sequence data leads to template pipelines. *Genome Biol. BioMed Central*; 2019 Oct 22;20(1):208–15.

Zapatka M, Borozan I, Brewer DS, Iskar M, Grundhoff A, Alawi M, et al. The landscape of viral associations in human cancers. *Nat Genet. Nature Publishing Group*; 2020 Feb 5;118(1):3030–12.

Connell SP, Hanna M, McCarthy F, Hurst R, Webb M, Curley H, et al. A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients. *BJU Int. John Wiley & Sons, Ltd* (10.1111); 2019 May 20;21:2163.

Webb M, Manley K, Olivan M, Guldvik I, Palczynska M, Hurst R, et al. Methodology for the at-home collection of urine samples for prostate cancer detection. *BioTechniques. Future Science Ltd London, UK*; 2020 Feb;68(2):65–71.

Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghorri M, et al. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. *Nat Genet. Nature Publishing Group*; 2018 Apr 16;387:70.

ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. *Nature. Nature Publishing Group*; 2020 Feb;578(7793):82–93.

BOB CHAMPION CANCER TRUST

**TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 30 JUNE 2019**

Financial Review

The net loss for the year was £87,331 (2018: £199,045) which include a surplus on fundraising events of £131,689 (2018: £88,508) and dividends received of £60,754 (2018: £62,862). In addition, unrealised gain on investments was £8,708 (2018: £50,183).

The Trustees are satisfied that the charity's funds are available and adequate to fulfil its obligations in relation to their commitments.

The Declaration of Trust, signed on the 29th June 1993, states that "any money available for investment may be so invested in the names of the Trustees or their nominees in any way whatsoever, whether or not producing income, as the Trustees shall in their absolute discretion think fit, as if they were absolutely entitled to the Trust Fund beneficially."

It is the policy of the charity to hold reserves in its General Fund that have not yet been committed or designated for any particular purpose. The Trustees have set aside these reserves in order to protect the future operations of the charity from the effects of any unforeseen variations in its income streams as part of a policy of good financial management practice.

Plans for the Future

The Trustees continue to work towards the aims of the deed of declaration of Trust to find a cure for urological cancers, particularly prostate cancer, through scientific and clinical research at The Institute of Cancer Research, The Royal Marsden Hospital and Bob Champion Research and Education Building at The Norwich Medical Research Park, UEA. To develop further the PUR urine test to detect prostate cancer cells remains at the forefront of the Trusts current plans.

The funding for the work of the Trust will continue to be raised from a full fundraising calendar run by the Executive Officers of the Charity, donations and legacies and the interest from the investment funds if required.

Statement of Trustees' Responsibilities

The trustees are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice.

The trustees are required to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and the incoming resources and application of resources, including the net income or expenditure, for the year. In preparing those financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Companies Act. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

BOB CHAMPION CANCER TRUST

**TRUSTEES' REPORT (continued)
FOR THE YEAR ENDED 30 JUNE 2019**


In so far as the trustees are aware:

- there is no relevant information of which the charity's independent examiner is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves.

Signed on behalf of the Trustees

DocuSigned by:

D17B32C730044CE...
Michael Cattermole
Trustee
Date: 22 April 2020

DocuSigned by:

F0FDE035330849C...
Timothy Fox
Trustee
Date: 22 April 2020

BOB CHAMPION CANCER TRUST

INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 30 JUNE 2019

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF BOB CHAMPION CANCER TRUST

We report to the charity Trustees on our examination of the accounts of the charity for the year ended 30 June 2019.

This report is made solely to the charity's Trustees, as a body, in accordance with section 145 of the Charities Act 2011 and regulations made under section 154 of that Act. Our work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an independent examiner's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's Trustees, as a body, for our work or for this report.

RESPONSIBILITIES AND BASIS OF REPORT

As the Trustees of the charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

We report in respect of my examination of the charity's accounts carried out under section 145 of the 2011 Act and in carrying out our examination we have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

INDEPENDENT EXAMINER'S STATEMENT

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. We confirm that we are qualified to undertake the examination because we are a member of ICAEW, which is one of the listed bodies.

We have completed our examination. We can confirm that no matters have come to our attention in connection with the examination giving us cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

BOB CHAMPION CANCER TRUST

**INDEPENDENT EXAMINER'S REPORT (continued)
FOR THE YEAR ENDED 30 JUNE 2019**

We have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed: 
6A7672EECF1144C...

Dated: 23 April 2020

Stuart Hinds ACA

for and on behalf of
Ecovis Wingrave Yeats UK Limited

Waverley House
7-12 Noel Street
London
W1F 8GQ

BOB CHAMPION CANCER TRUST

**STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 30 JUNE 2019**

	Note	Unrestricted funds 2019 £	Total funds 2019 £	Total funds 2018 £
INCOME AND ENDOWMENTS FROM:				
Donations and legacies	2	55,351	55,351	20,007
Charitable activities:				
Other charitable activities	3	297,347	297,347	160,906
Investments	4	61,030	61,030	62,873
TOTAL INCOME AND ENDOWMENTS		413,728	413,728	243,786
EXPENDITURE ON:				
Raising funds	3	165,658	165,658	72,398
Charitable activities:				
Research grants	5	233,366	233,366	307,767
Support costs	6	100,090	100,090	82,943
Governance	7	10,653	10,653	29,906
TOTAL EXPENDITURE	8	509,767	509,767	493,014
NET BEFORE INVESTMENT GAINS		(96,039)	(96,039)	(249,228)
Net gains on investments	12	8,708	8,708	50,183
NET EXPENDITURE BEFORE OTHER RECOGNISED GAINS AND LOSSES		(87,331)	(87,331)	(199,045)
NET MOVEMENT IN FUNDS		(87,331)	(87,331)	(199,045)
RECONCILIATION OF FUNDS:				
Total funds brought forward		1,605,121	1,605,121	1,804,166
TOTAL FUNDS CARRIED FORWARD		1,517,790	1,517,790	1,605,121

The notes on pages 12 to 23 form part of these financial statements.

BOB CHAMPION CANCER TRUST

BALANCE SHEET
AS AT 30 JUNE 2019

	Note	£	2019 £	£	2018 £
FIXED ASSETS					
Tangible assets	11		4,358		6,110
Investments	12		1,591,208		1,582,500
			1,595,566		1,588,610
CURRENT ASSETS					
Debtors	13	13,274		45,389	
Cash at bank and in hand		45,474		198,260	
		58,748		243,649	
CREDITORS: amounts falling due within one year	14	(136,524)		(227,138)	
NET CURRENT (LIABILITIES)/ASSETS			(77,776)		16,511
NET ASSETS			1,517,790		1,605,121
CHARITY FUNDS					
Unrestricted funds			1,517,790		1,605,121
TOTAL FUNDS			1,517,790		1,605,121

The financial statements were approved by the Trustees on 22 April 2020 and signed on their behalf, by:

DocuSigned by:

D17B32C730044CE...
Michael Cattermole
Trustee

DocuSigned by:

F0FDE035330849C...
Timothy Fox
Trustee

The notes on pages 12 to 23 form part of these financial statements.

BOB CHAMPION CANCER TRUST

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2019**

1. ACCOUNTING POLICIES**1.1 Basis of preparation of financial statements**

The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to these accounts. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014 and Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and Charities Act 2011.

Bob Champion Cancer Trust constitutes a public benefit entity as defined by FRS 102.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published on 16 July 2014 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

The charity has taken advantage of the exemption available to smaller charities from preparing a cash flow statement.

1.2 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

1.3 Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Donated services or facilities are recognised when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general volunteer time of the Friends is not recognised and refer to the Trustees' report for more information about their contribution.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

BOB CHAMPION CANCER TRUST

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2019

1. ACCOUNTING POLICIES (continued)

1.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include project management carried out at Headquarters. Governance costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in charitable activities that raise funds.

Charitable activities and Governance costs are costs incurred on the charity's operations, including support costs and costs relating to the governance of the charity apportioned to charitable activities.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

1.5 Going concern

The Trustees consider that there are no material uncertainties about the Trust's ability to continue as a going concern for a period of at least twelve months after the date of signature of these accounts.

1.6 Tangible fixed assets and depreciation

A review for impairment of a fixed asset is carried out if events or changes in circumstances indicate that the carrying value of any fixed asset may not be recoverable. Shortfalls between the carrying value of fixed assets and their recoverable amounts are recognised as impairments. Impairment losses are recognised in the Statement of financial activities.

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Fixtures and fittings	-	20% reducing balance
Computer equipment	-	25% reducing balance

BOB CHAMPION CANCER TRUST

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2019**

1. ACCOUNTING POLICIES (continued)**1.7 Investments**

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance sheet date, unless fair value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and (losses), whether realised or unrealised, are combined and shown in the heading 'Net losses on investments' in the Statement of financial activities.

1.8 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the Bank.

1.9 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.10 Cash at Bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.11 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

1.12 Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.13 Pensions

The charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the charity to the fund in respect of the Year.

BOB CHAMPION CANCER TRUST

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2019**

1. ACCOUNTING POLICIES (continued)

1.14 Critical accounting estimates and areas of judgment

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The Trustees have not applied any significant estimates or judgments in the preparation of these financial statements.

1.15 Basis of non-consolidation

In the opinion of the Trustees, the charity and its subsidiary undertakings comprise a small group. The subsidiary has been excluded as its inclusion would not be material from the point of view of providing a true and fair view.

2. INCOME FROM DONATIONS AND LEGACIES

	Unrestricted funds 2019 £	Total funds 2019 £	<i>Total funds 2018 £</i>
League of Friends	3,480	3,480	5,000
Memorial	44,512	44,512	3,615
Other	7,359	7,359	11,392
	<hr/>	<hr/>	<hr/>
Total donations and legacies	55,351	55,351	20,007
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

In both the current year and prior year all income from donations and legacies was in relation to unrestricted funds.

BOB CHAMPION CANCER TRUST

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2019**

3. ACTIVITIES FOR GENERATING FUNDS

	Unrestricted funds 2019 £	Total funds 2019 £	<i>Total funds 2018 £</i>
Charity income			
Tennis Tournament	16,660	16,660	19,940
Champions Willberry race	86,602	86,602	-
Chepstow Jump Legends	12,173	12,173	23,592
Christmas Season	35,447	35,447	41,250
General fundraising	43,492	43,492	35,771
Carols and Champagne	64,162	64,162	-
Shetland Pony Grand National	38,811	38,811	40,353
	<u>297,347</u>	<u>297,347</u>	<u>160,906</u>
Fundraising expenses			
Expenditure on events	133,893	133,893	42,624
Bob Champion retainer	26,500	26,500	26,000
Bob Champion expenses	5,265	5,265	3,774
	<u>165,658</u>	<u>165,658</u>	<u>72,398</u>
Net income from activities for generating funds	<u><u>131,689</u></u>	<u><u>131,689</u></u>	<u><u>88,508</u></u>

4. INVESTMENT INCOME

	Unrestricted funds 2019 £	Total funds 2019 £	<i>Total funds 2018 £</i>
Listed securities	60,754	60,754	62,862
Bank deposits	276	276	11
Total 2019	<u><u>61,030</u></u>	<u><u>61,030</u></u>	<u><u>62,873</u></u>
<i>Total 2018</i>	<u><u>62,873</u></u>	<u><u>62,873</u></u>	

In both the current year and prior year all investment income was in relation to unrestricted funds.

BOB CHAMPION CANCER TRUST

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2019**

5. RESEARCH GRANTS

	Grants to Institutions 2019 £	Total 2019 £	<i>Total 2018 £</i>
Building project - The Bob Champion Research and Education Building at the University of East Anglia (UEA)	50,000	50,000	<i>137,500</i>
Professor Rosalind Eeles grant - Institute of Cancer Research (ICR)	75,000	75,000	<i>100,000</i>
Bob Champion Cancer Trust Post Doctoral fellowship grant - ICR	62,366	62,366	<i>41,577</i>
Professor Colin Cooper grant - UEA	46,000	46,000	<i>28,690</i>
	233,366	233,366	<i>307,767</i>
Total 2019	233,366	233,366	<i>307,767</i>
<i>Total 2018</i>	<i>307,767</i>	<i>307,767</i>	

The Bob Champion Research and Education Building is based on the Norwich Research Park and operated by the University of East Anglia in partnership with the Norfolk & Norwich University Hospital. This centre, opened February 2015, provides state-of-the-art laboratories for researchers, plus a unique bio-bank facility to store DNA and tissue samples as well as undergraduate and post graduate education. The trust has pledged £750,000 towards the project payable over a five year period, 2015-2019. As at 30 June 2019, £682,500 (2018 - £562,500) has been donated towards the project.

Professor Ros Eeles, Prostate Cancer Sequencing Project at the ICR, commenced in March 2014 at cost of £500,000 over the five year grant period, and has now been paid in full. A continuation grant for further work with Professor Eeles has been approved for advanced prostate cancer research over a three year period totalling £282,509.

Dr Marianna Buongiorno, appointed in November 2017 for three years at a cost of £188,000, held the position of the Bob Champion Post - doctoral fellowship within Dr Gert Attard's team at the ICR. During the year Dr Mahedi Hassan replaced Dr Marianna Buongiorno in the Bob Champion Post - Doctoral Fellowship within Dr Gert Attard's team at the ICR. Dr Gert Attard is Affiliate Team Leader for the Centre for Evolution and Cancer at the ICR and Team Leader of Treatment Resistance Research Group at UCL.

Professor Colin Cooper, The Role of Bacterial Infection in the Development of Human Prostate Cancer grant for Rachel Hurst was awarded in October 2017 for two years at a cost of £92,000 and has been extended for a further two years at £40,000 per annum commencing January 2020. Professor Cooper is Professor of Cancer Genetics and Associate Dean of Research at UEA.

BOB CHAMPION CANCER TRUST

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2019**

6. SUPPORT COSTS

	Premises costs £	Other costs £	Personnel costs £	Total 2019 £	<i>Total 2018 £</i>
Rent, light and heat	9,210	-	-	9,210	8,448
Telephone	1,463	-	-	1,463	2,356
Insurance	2,671	-	-	2,671	1,638
Equipment hire	-	1,042	-	1,042	865
Advertising and PR	-	1,035	-	1,035	4,584
Printing, postage and stationery	-	1,593	-	1,593	537
General expenses	-	4,200	-	4,200	6,852
Travel	-	605	-	605	1,535
Bank interest and charges	-	265	-	265	220
Credit charges	-	1,907	-	1,907	1,342
Depreciation	-	1,513	-	1,513	2,012
Fixed assets write-off	-	239	-	239	-
Wages and salaries	-	-	69,078	69,078	66,702
National insurance	-	-	3,869	3,869	4,560
Pension cost	-	-	1,400	1,400	757
Total 2019	13,344	12,399	74,347	100,090	102,408
<i>Total 2018</i>	<i>12,442</i>	<i>17,947</i>	<i>72,019</i>	<i>102,408</i>	

7. GOVERNANCE COSTS

	Unrestricted funds 2019 £	Total funds 2019 £	<i>Total funds 2018 £</i>
Independent examiner fees	5,250	5,250	4,950
Accounting fees	5,390	5,390	5,050
Legal fees	13	13	441
	10,653	10,653	10,441

BOB CHAMPION CANCER TRUST

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2019**

8. ANALYSIS OF EXPENDITURE BY EXPENDITURE TYPE

	Staff costs 2019 £	Other costs 2019 £	Total 2019 £	Total 2018 £
Expenditure on fundraising	-	165,658	165,658	72,398
Costs of raising funds	-	165,658	165,658	72,398
Premises costs	-	13,344	13,344	12,442
Other costs	-	12,399	12,399	17,947
Personnel costs	74,347	-	74,347	72,019
Building project at UEA - The Bob Champion Research and Education Building	-	50,000	50,000	137,500
Professor Rosalind Eeles grant - Institute of Cancer Research	-	75,000	75,000	100,000
Dr. Attard grant	-	62,366	62,366	41,577
Professor Colin Cooper grant - University of East Anglia	-	46,000	46,000	28,690
Charitable activities	74,347	259,109	333,456	410,175
Expenditure on governance	-	10,653	10,653	10,441
Total 2019	74,347	435,420	509,767	493,014
Total 2018	72,019	420,995	493,014	

9. NET INCOME/(EXPENDITURE)

This is stated after charging:

	2019 £	2018 £
Depreciation of tangible fixed assets:		
- owned by the charity	1,513	2,012
Independent examiner fees	5,250	4,950

During the Year, no Trustees received any remuneration (2018 - £Nil).

During the Year, no Trustees received any benefits in kind (2018 - £Nil).

During the Year, no Trustees received any reimbursement of expenses (2018 - £Nil).

BOB CHAMPION CANCER TRUST

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2019**

10. STAFF COSTS

Staff costs were as follows:

	2019	<i>2018</i>
	£	£
Wages and salaries	69,078	66,702
Social security costs	3,869	4,560
Other pension costs	1,400	757
	74,347	72,019

The average number of persons employed by the charity during the year was as follows:

2019	<i>2018</i>
No.	No.
2	2

No employee received remuneration amounting to more than £60,000 in either year.

The total employment benefits of key management personnel were £50,520 (*2018 - £48,630*).

11. TANGIBLE FIXED ASSETS

	Fixtures and fittings £	Computer equipment £	Total £
Cost			
At 1 July 2018	2,221	37,751	39,972
Disposals	(2,221)	(30,969)	(33,190)
At 30 June 2019	-	6,782	6,782
Depreciation			
At 1 July 2018	1,922	31,940	33,862
Charge for the Year	60	1,453	1,513
On disposals	(1,982)	(30,969)	(32,951)
At 30 June 2019	-	2,424	2,424
Net book value			
At 30 June 2019	-	4,358	4,358
<i>At 30 June 2018</i>	<i>299</i>	<i>5,811</i>	<i>6,110</i>

BOB CHAMPION CANCER TRUST

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2019**

12. FIXED ASSET INVESTMENTS

	Listed Investments £	Investment in Aldaniti Trading Company Limited £	Total £
Market value			
At 1 July 2018	1,582,498	2	1,582,500
Revaluations	8,708	-	8,708
	<hr/>	<hr/>	<hr/>
At 30 June 2019	1,591,206	2	1,591,208
	<hr/>	<hr/>	<hr/>

Subsidiary undertakings

The following were subsidiary undertakings of the company:

Name	Holding
Aldaniti Trading Company Limited	100%

The aggregate of the share capital and reserves as at 30 June 2019 and of the profit or loss for the year ended on that date for the subsidiary undertakings were as follows:

Name	Aggregate of share capital and reserves £	Profit/(loss) £
Aldaniti Trading Company Limited	2	-
	<hr/>	<hr/>

At 30 June 2019 M&G Securities Limited, an investment management company external to the charity, valued the Charifund income units at £608,926 (2018 - £623,267). The Global dividend units were valued at £755,740 (2018 - £732,918) and the Optimal income units were valued at £226,540 (2018 - £226,313). This valuation was made on the basis of the value of the units on the open market in which they are traded. The gain is included in the statement of financial activities.

Aldaniti Trading Company Limited, a company incorporated in England and Wales, ceased trading on 30 June 2004. On this date its trade and assets were transferred to the charity.

13. DEBTORS

	2019 £	2018 £
Other debtors	-	8
Prepayments and accrued income	13,274	45,381
	<hr/>	<hr/>
	13,274	45,389
	<hr/>	<hr/>

BOB CHAMPION CANCER TRUST

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2019**

14. CREDITORS: Amounts falling due within one year

	2019 £	2018 £
Accruals - grants	94,801	180,421
Amounts owed to group undertakings	2	2
Other taxation and social security	1,176	257
Other creditors	443	1,844
Accruals and deferred income	40,102	44,614
	<u>136,524</u>	<u>227,138</u>

Deferred income

	2019 £
Amounts deferred in the current year	16,740
Deferred income at 30 June 2019	<u>16,740</u>

Income has been deferred for payments received in advance of events scheduled to happen after the year-end for the purpose of generating funds. As at 1 July 2018, deferred income was £26,241.

15. FINANCIAL INSTRUMENTS

	2019 £	2018 £
Financial assets measured at fair value through income and expenditure	1,591,206	1,582,498
Financial assets measured at amortised cost	-	8
	<u>1,591,206</u>	<u>1,582,506</u>
Financial liabilities measured at amortised cost	<u>(156,524)</u>	<u>(277,138)</u>

Financial assets measured at fair value through income and expenditure comprise fixed asset investments. Fair value has been determined on the basis of the value of the investment units on the open market in which they are traded.

Financial assets measured at amortised cost comprise other debtors.

Financial liabilities measured at amortised cost comprise accruals, amounts owed to subsidiaries and the wages control account.

BOB CHAMPION CANCER TRUST

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2019**

16. PENSION COMMITMENTS

The charity operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the charity in an independently administered fund. The pension cost charge represents contributions payable by the charity to the fund and amounted to £1,400 (2018 - £757). Contributions totalling £328 (2018 - £227) were payable to the fund at the balance sheet date and are included in creditors.

17. RELATED PARTY TRANSACTIONS

During the year, the charity paid £31,766 (2018 - £29,774) to the president of the charity, Mr. Bob Champion, in relation to fees and expenses incurred in fulfilling his duties. The amount outstanding at the year end was £7,634 (2018 - £7,445). Bob Champion's retainer has been approved by the Charity Commission.